A5075002877- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders Research
- Cutaneous lymphoproliferative disorders research
- COVID-19 Clinical Research Studies
- Rheumatoid Arthritis Research and Therapies
- Musculoskeletal Disorders and Rehabilitation
- Autoimmune Bullous Skin Diseases
- COVID-19 and Mental Health
- Musculoskeletal pain and rehabilitation
- Pain Mechanisms and Treatments
- Nonmelanoma Skin Cancer Studies
- Spondyloarthritis Studies and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chronic Disease Management Strategies
- COVID-19 Impact on Reproduction
- Pharmacovigilance and Adverse Drug Reactions
- Body Image and Dysmorphia Studies
- Cutaneous Melanoma Detection and Management
- Respiratory viral infections research
- Osteoarthritis Treatment and Mechanisms
- COVID-19 and healthcare impacts
- Inflammatory Bowel Disease
Keele University
2001-2025
Versus Arthritis
2022-2025
Vassar College
2023-2024
University of Manchester
2011-2023
NIHR Manchester Biomedical Research Centre
2017-2023
Manchester Academic Health Science Centre
2018-2022
Salford Royal NHS Foundation Trust
2018-2022
Digital Research Alliance of Canada
2021
Psoriasis Association
2021
King's College London
2021
Real‐world biologic drug survival is an important proxy measure for effectiveness. Predictors of may help patients with psoriasis choose between therapies. (i) To assess the relative adalimumab, ustekinumab and secukinumab in psoriasis. (ii) investigate predictors survival. A prospective cohort study was performed British Association Dermatologists Biologics Immunomodulators Register (BADBIR) November 2007 August 2019. We analysis fitted a flexible parametric model discontinuation due to...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
Biologic therapies have revolutionized the treatment of moderate‐to‐severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. To evaluate demographic, social and clinical factors that could be used predict effectiveness stratify biologic in Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic‐naive starting biologics with outcome data at 6 (n = 3079) 12 3110) months. Associations...
Patients with psoriasis enrolled in clinical trials of biologics may not be representative the real-world population. There is evidence that patients ineligible for such have a greater risk serious adverse events (SAEs), but effect on drug discontinuation and effectiveness are unknown.To determine whether (1) discontinuation, (2) effectiveness, (3) rates SAEs differ categorized as eligible or trials.An observational study using 157 dermatology centers United Kingdom Republic Ireland was...
This large prospective cohort study provides insights into the differential drug survival of second-line biologic therapies in routine clinical practice. We found that 77% patients who were switched to a second therapy continued receive new treatment for at least 12 months. shows clearly experiencing failure with one can benefit from switching another. However, discontinuation due AEs was more common among those discontinued first-line because AEs. The results this should support decision...
Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed "real-world" levels of self-reported to conventional and biologic systemic therapies used psoriasis evaluated psychological biomedical factors associated with using multivariable analyses. Latent profile analysis was investigate whether patients can be categorized into groups similar medication beliefs. categorizes individuals profiles on set continuous variables discrete represented by categorical latent...
Mason K, Thygesen LC, Stenager E, Brønnum-Hansen H, Koch-Henriksen N. Evaluating the use and limitations of Danish National Patient Register in register-based research using an example multiple sclerosis. Acta Neurol Scand: 2012: 125: 213–217. © 2011 John Wiley & Sons A/S. Background – The Register, Landspatientregistret (LPR), is a register all hospital discharges outpatient treatments Denmark. Aims It increasingly used so it important to understand what extent this can be as accurate...
Abstract Background The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. Objectives To compare the risk major events ( CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque treated adalimumab, etanercept or ustekinumab a large prospective cohort. Methods Prospective cohort study examining comparative s was conducted using British Association Dermatologists Biologics Immunomodulators Register. main...
Real-world data evaluating effectiveness and persistence of systemic therapies for patients with psoriasis are limited. Objectives To determine the acitretin, ciclosporin, fumaric acid esters (FAEs) methotrexate in moderate-to-severe psoriasis.Data from British Association Dermatologists Biologics Immunomodulators Register (BADBIR), a prospective, multicentre pharmacovigilance register receiving biologic and/or conventional therapies, were analysed. Eligible ≥ 16 years age first course FAEs...
Abstract Background The current management of psoriasis does not differentiate between young and old patients in selecting the safest and/or most effective biologic. Objectives To explore effect age at treatment initiation response to biologics with moderate-to-severe UK Eire. Methods Data from registering British Association Dermatologists Biologics Immunomodulators Register (BADBIR) 2007-2024 on first course Tumour Necrosis Factor (TNF), interleukin (IL) 12/13, IL-17 IL-23 inhibitors (i)...
Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared patients no treatments.We used international patient survey to explore the hypothesis greater risk-mitigating behaviour in those may account, at least part, for this observation.Online surveys were completed by individuals psoriasis (globally) or rheumatic and musculoskeletal (RMDs) (UK only)...
Patients recruited in randomized controlled trials (RCTs) for biologic therapies psoriasis are not fully representative of the real‐world population. Firstly, to investigate whether patient characteristics associated with being included a RCT. Secondly, estimate differences incidence severe adverse events (SAEs) and response rate between RCT populations patients on using standardization method. Data from British Association Dermatologists Biologics Immunomodulators Register (BADBIR) were...
Treatments for psoriasis may be less effective in everyday practice than clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide treatment effect estimates that are robust inform both clinicians regulatory bodies.To assess comparative effectiveness ustekinumab secukinumab patients with psoriasis, to test whether relative estimate CLEAR trial, randomized compared replicated.This research...
The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium has a collective aim develop prescribing algorithm help stratify eligible patients with psoriasis the most appropriate biological treatment. To facilitate adoption of stratified approach, it is necessary first understand factors driving choice first-line therapy.To identify and quantify that influence selection therapy for people psoriasis.Multinomial logistic regression was used determine influenced probability...
Abstract Background and aims: Amplification of sensory signalling within the nervous system along with psychosocial factors contributes to variation severity knee pain. Quantitative testing (QST) is a non-invasive test battery that assesses perception thermal, pressure, mechanical vibration stimuli used in assessment Psychosocial also have an important role explaining occurrence The aim was determine whether QST measures were associated self-reported pain, those associations mediated by...